A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia

Abstract

Increases in serum prolactin concentrations after administration of risperidone have been attributed, by some, to the availability of paliperidone in plasma. This double-blind, randomized, parallel-group study in patients with schizophrenia compared serum prolactin concentrations following the administration of paliperidone extended-release and risperidone immediate-release tablets. At steady state, the doses administered resulted in a similar exposure to paliperidone and the pharmacologically active fraction of risperidone (i.e. risperidone + paliperidone), respectively. Eligible patients were randomized to either paliperidone extended-release 12 mg on days 1—6 or risperidone immediate-release 2 mg on day 1 and 4 mg on days 2—6. Mean serum prolactin concentrations increased on day 1 (C_max: 71.8 ng/ml and 89.7 ng/ml reached at 6.5 hours and 2.6 hours for paliperidone extended-release and risperidone immediate-release, respectively). On day 6, serum prolactin concentration—time profiles were similar for both treatments, with overall higher serum prolactin concentrations than on day 1 (AUC_{0—24 h}: 1389 and 842 ng h/ml, and 1306 and 741 ng.h/ml on day 6 and day 1 for paliperidone extended-release and risperidone immediate-release, respectively). These results indicate that paliperidone extended-release 12 mg and risperidone immediate-release 4 mg, administered over a period of 6 days, lead to similar elevations in serum prolactin concentrations.

Keywords

paliperidone pharmacokinetic prolactin risperidone

Get full access to this article

View all access options for this article.

References

Beasley C., Jr , Sanger T. , Satterlee W. , et al. (1996) Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124: 159-167.

Bouchard RH , Merette C. , Pourcher E. , et al. (2000) Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group. J Clin Psychopharmacol 20: 295-304.

Cleton A. , Rossenu S. , Talluri K. , et al. (2007) Evaluation of the pharmacokinetics of an extended-release formulation of paliperidone and an immediate-release formulation of risperidone. Clin Pharm Rev 81(Suppl 1): S62.

Csernansky JG , Mahmoud R. , Brenner R. ( 2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346: 16-22.

Daniel DG , Copeland LF ( 2000) Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic. Expert Opin Investig Drugs 9: 819-828.

Davis JM , Chen N. , Glick ID ( 2003) A meta-analysis of the efficacy of second-generation antipsychotics . Arch Gen Psychiatry 60: 553-564.

Dossenbach M. , Dyachkova Y. , Pirildar S. , et al. (2006) Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry 21: 251-258.

Eberhard J. , Lindstrom E. , Holstad M. , Levander S. ( 2007) Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand 115: 268-276.

Heykants J. , Huang ML , Mannens G. , et al. (1994) The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 55(Suppl): 13-17.

10.

Invega Prescribing Information (2006) Janssen Pharmaceuticals, Titusville, NJ, USA. Available at http://www.fdagiov/cder/foi/label/2006/021999lblpdf : (accessed January 2007).

11.

Kane JM , Cooper TB , Sachar EJ , Halpern FS , Bailine S. ( 1981) Clozapine: plasma levels and prolactin response . Psychopharmacology (Berl) 73: 184-187.

12.

Karlsson P. , Dencker E. , Nyberg S. , et al. (2006) Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies. Clin Pharmacol Ther 79: 74(PIII-57).

13.

Kinon BJ , Gilmore JA , Liu H. , Halbreich UM ( 2003) Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 28(Suppl 2): 69-82.

14.

Kleinberg DL , Davis JM , de Coster R. , Van Baelen B. , Brecher M. ( 1999) Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 19: 57-61.

15.

Knegtering R. , Baselmans P. , Castelein S. , Bosker F. , Bruggeman R. , van den Bosch RJ ( 2005) Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 162: 1010-1012.

16.

Mannens G. , Huang ML , Meuldermans W. , Hendrickx J. , Woestenborghs R. , Heykants J. ( 1993) Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 21: 1134-1141.

17.

Marder SR , Davis JM , Chouinard G. ( 1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58: 538-546.

18.

Megens AA , Awouters FHL ( 1994) In vivo pharmacological profile of 9-hydroxyrisperidone the major metabolite of the novel antipsychotic risperidone. Drug Dev Res 33: 399-412.

19.

Melkersson K. ( 2005) Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 66: 761-767.

20.

Melkersson KI ( 2006) Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol 21: 529-532.

21.

Nokin J. , Vekemans M. , L’Hermite M. , Robyn C. ( 1972) Circadian periodicity of serum prolactin concentration in man. Br Med J 3: 561-562.

22.

Nordstrom AL , Farde L. ( 1998) Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol 18: 305-310.

23.

Remmerie BM , Sips LL , de Vries R. , et al. (2003) Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 783: 461-472.

24.

Rossenu S. , Cleton A. , Talluri K. , et al. (2008) Pharmacodynamics of paliperidone extended-release tablets and immediate-release risperidone in schizophrenia. Schizophr Res 98: 159.

25.

Schotte A. , Janssen PF , Gommeren W. , et al. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124: 57-73.

26.

Troost PW , Lahuis BE , Hermans MH , et al. (2007) Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol 27: 52-57.

27.

Volavka J. , Czobor P. , Cooper TB , et al. (2004) Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol . J Clin Psychiatry 65: 57-61.